Search

Your search keyword '"Persico, E."' showing total 162 results
Start Over Author "Persico, E."
162 results on '"Persico, E."'

6. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C

Author

Persico, M., Capasso, M., Russo, R., Persico, E., Croce, L., Tiribelli, C., and Iolascon, A.

Subjects
Cytokines -- Genetic aspects, Cytokines -- Research, Genetic polymorphisms -- Research, Hepatitis -- Genetic aspects, Hepatitis -- Development and progression, Hepatitis -- Care and treatment, Antiviral agents -- Dosage and administration, Antiviral agents -- Research, Health
Published
2008

11. Innovazione didattica e sviluppo professionale dei docenti: il caso METIS

Author

Donatella Persico e Francesca Pozzi

Subjects
tecnologie didattiche, formazione docenti, innovazione didattica, progetto METIS, learning design
Abstract

Lo sviluppo professionale dei docenti è il principale fattore abilitante per l'innovazione dei sistemi formativi. Nel contributo viene introdotto il concetto di Learning Design e vengono illustrate le sue promesse in termini di innovazione educativa; inoltre viene proposto un approccio per lo sviluppo professionale dei docenti e viene descritta una prima esperienza di applicazione di tale modello. Grazie ai risultati ottenuti nel contesto descritto, il contributo propone anche alcune indicazioni per i decision makers: criteri per le politiche in merito allo sviluppo professionale dei docenti, alle politiche scolastiche in generale e alla ricerca.

Published
2015

12. SOCS3 and IRS-1 Gene Expression Differs Between Genotype 1 and Genotype 2 HCV-Infected HEPG2 Cells

Author

PERSICO, LICER ENRICO ANGELO, RUSSO, RAFFAELE, CAPASSO, MARTA, TIRIBELLI, CLAUDIO, Persico, E, Svelto, M, Spano, D, Andolfo, I, La Mura, V, Torella, R, Iolascon, A., Persico, LICER ENRICO ANGELO, Russo, Raffaele, Persico, E, Svelto, M, Spano, D, Andolfo, I, La Mura, V, Capasso, Marta, Tiribelli, Claudio, Torella, R, and Iolascon, A.

Subjects
Gene Expression Regulation* Genotype Hep G2 Cells Hepacivirus/physiology* Hepatitis C/genetics* Hepatitis C/metabolism Humans Insulin Receptor Substrate Proteins/genetics* Insulin Receptor Substrate Proteins/metabolism* Proto-Oncogene Proteins c-akt/metabolism Suppressor of Cytokine Signaling Proteins/genetics* Suppressor of Cytokine Signaling Proteins/metabolism* Virus Replication
Abstract

BACKGROUND: The poor response to antiviral treatment of hepatitis C virus (HCV)-infected patients with genotype 1b has been associated with a higher prevalence of metabolic syndrome. However, the molecular link between these clinical entities is not clear. The goal of this study was to clarify the role of genotype 1b and 2 in the genetic expression of suppressor of cytokine signaling 3 (SOCS3) and insulin receptor substrate 1 (IRS-1). METHODS: We infected human hepatocellular carcinoma cell line (HepG2) cells with human HCV genotype 1b or 2 and measured the gene and protein expression of SOCS3 at various times. We also evaluated impairment in the insulin pathway by analysis of IRS-1 and phospho-AKT. For the control, we used HepG2 cell cultures treated with non-infectious serum. We also demonstrated the occurrence of HCV infection by the detection of both positive and negative strands in the cells and culture medium. To test infection of the HepG2 cells, we performed quantitative real-time polymerase chain reaction (qRT-PCR) of viral load at different time points. We analyzed the viral genotype in the pellet and supernatant. RESULTS: At each time point, we found positive and negative strands in the infected cells, while in the medium we found positive, but no negative strands. We also detected the presence of the correct genotype in the medium. Two weeks following infection when the viral load was higher, we tested genotype 1b and 2 infected cells. SOCS3 gene expression was significantly higher in genotype 1b-infected cells (median 2.56; mean 2.82+/-0.59) compared with genotype 2 (median 1.34; mean 1.46+/-0.31) (p=0.04) and control cells (median 1.09; mean 1.02+/-0.11, p=0.02). There was no difference between cells exposed to genotype 2 and control cells. Conversely, IRS-1 was significantly lower in genotype 1b-infected cells (median 15.97; mean 15.45+/-0.67) compared with genotype 2-infected cells (median 16.45; mean 16.44+/-0.01, p=0.04). Statistically significant differences were seen when comparing the pAKT/AKT ratio in genotype 1b-infected cells (0.19+/-0.034) and not genotype 1b-infected (genotype 2-infected and non-infected) cells (0.253+/-0.004, p=0.03). This inverse regulation is compatible with interactions between the molecular expression of SOCS3, IRS-1 and phospho-AKT mediated by the genotype 1b virus. CONCLUSIONS: Up-regulation of the SOCS3 gene might be one of the mechanisms governing non-response to therapy and expression of insulin resistance mediated via a direct mechanism at this level of genotype 1b HCV.

Published
2009

14. Capitolo I Il sistema centrale di controllo e comando

Author

Ageno, M., Quaranta, A. Alberigi, Amman, F., Bernardini, C., Bizzarri, U., Bologna, G., Corazza, G., Diambrini, G., Ghigo, G., Habel, R., Infante, C., Massarotti, A., Moneti, G., Murtas, G. P., Persico, E., Puglisi, M., Quercia, I. F., Querzoli, R., Sacerdoti, G., Salvini, G., Sanna, G., Sircana, S., Sona, P. G., Toschi, R., and Turrin, A.

Published
1962
Full Text
View/download PDF

19. Rivista

Author

Persico, E., Pierucci, M., Carrelli, A., Carrelli, F., Brunetti, R., and Ronchi, Vasco

Published
1922
Full Text
View/download PDF

20. Capitolo I L’elettrosincrotrone

Author

Ageno, M., Quaranta, A. Alberigi, Amman, F., Bernardini, C., Bizzarri, U., Bologna, G., Corazza, G., Diambrini, G., Ghigo, G., Habel, R., Infante, C., Massarotti, A., Moneti, G., Murtas, G. P., Persico, E., Puglisi, M., Quercia, I. F., Querzoli, R., Sacerdoti, G., Salvini, G., Sanna, G., Sircana, S., Sona, P. G., Toschi, R., and Turrin, A.

Published
1962
Full Text
View/download PDF

26. Rivista

Author

Carrelli, A., Persico, E., G. A. P., Sellerio, A., and Pierucci, M.

Published
1923
Full Text
View/download PDF

28. Capitolo I La ricerca del fascio

Author

Ageno, M., Quaranta, A. Alberigi, Amman, F., Bernardini, C., Bizzarri, U., Bologna, G., Corazza, G., Diambrini, G., Ghigo, G., Habel, R., Infante, C., Massarotti, A., Moneti, G., Murtas, G. P., Persico, E., Puglisi, M., Quercia, I. F., Querzoli, R., Sacerdoti, G., Salvini, G., Sanna, G., Sircana, S., Sona, P. G., Toschi, R., and Turrin, A.

Published
1962
Full Text
View/download PDF

29. Rivista

Author

Polvani, G., Fermi, E., Maghieru, I., Pierucci, M., Pontremoli, A., Polvani, G., Persico, E., Rasetti, F., Paris, M., Valle, G., Brunetti, R., Brunetti, E., Perucca, E., Pontremoli, A., Pierucci, M., and Polvanl, G.

Published
1922
Full Text
View/download PDF

33. Hepatitis G virus in patients with Hodgkin's lymphoma

Author

Marcello Persico, Renzo, A. D., Persico, E., Notaro, R., Torella, R., and Rotoli, B.

Subjects
Hepatitis, Viral, Human, complications, analysis, Flaviviridae, isolation /&/ purification, Hematology, Hodgkin Disease, Hepatitis, virology, isolation /&/ purification, Hepatitis, Viral, Human, complications, Hodgkin Disease, virology, Humans, RNA, RNA, Viral, Humans, RNA
Published
1998

43. Operation at 1000 MeV of the frascati electronsynchrotron

Author

Alberigi, A., Amman, F., Bernardini, C., Bizzarri, U., Bologna, G., Corazza, G., Diambrini, G., Ghigo, G., Massarotti, A., Murtas, G. P., Puglisi, M., Quercia, I. F., Querzoli, R., Sacerdoti, G., Salvini, G., Sanna, G., Sona, P. G., Toschi, R., Turrin, A., Ageno, M., and Persico, E.

Published
1959
Full Text
View/download PDF

44. Determination of chemical purity and specific activity of 177g,mLuCl3 by INAA and ET-AAS.

Author

Groppi, F., Persico, E., Quartapelle, E., Gallorini, M., Bergamaschi, L., and Cantone, M.

Subjects
*SOLUTION (Chemistry), *OXIDATION, *NUCLEAR reactors, *ATOMIC absorption spectroscopy, *RADIOTHERAPY, *RADIOIMMUNOTHERAPY
Abstract

Radioactive solutions of 177g,mLuIIICl3 are used for labeling organic compounds for metabolic radiotherapy and radioimmunotherapy. The labeling process involves Lu in III oxidation state, so the presence of other stable impurities in the same oxidation state could result in an isomorphous dilution of radioactive 177gLu. Samples of 177gLuCl3 were analyzed to quantify the chemical impurities with a special regard for trivalent elements with instrumental neutron activation analysis (INAA), carried out in the research nuclear reactor TRIGA MARK II (GA, USA) of the Università degli Studi di Pavia, and electrothermal atomic absorption spectroscopy (ET-AAS) (Varian, USA) at LASA. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

45. Accurate determination of half-life and radionuclidic purity of reactor produced 177gLu (177mLu) for metabolic radiotherapy.

Author

Canella, L., Bonardi, M. L., Groppi, F., Persico, E., Zona, C., Menapace, E., Alfassi, Z. B., Chinol, M., Papi, S., and Tosi, G.

Subjects
RADIOACTIVE decay, HALF-life (Nuclear physics), NUCLEAR medicine, RADIOTHERAPY, RADIOISOTOPES, NEGATIVE resistance devices
Abstract

Thanks to its favorable decay characteristics, 177gLu is finding several applications in nuclear medicine, especially for palliative metabolic radiotherapy of cancer and radioimunotherapy. 177gLu is produced in thermal nuclear reactor either by direct neutron capture 176Lu(n,γ)177(m+g)Lu on either natural or enriched 176Lu target, or by reaction on enriched 176Yb target followed by negatron decay. The latter method does produce a high radionuclidic purity and high specific activity radionuclide in no-carrier-added form, since 177Yb decays solely to the ground state 177gLu. Conversely, the first method does produce a low specific activity 177gLu in carrier-added form,1 contaminated by the long-lived radioisotopic impurity 177mLu. The accurate determination of radionuclidic purity and half-life of 177gLu carried out by HPGe and LSCS is presented in some details. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

46. Wet-chemistry method for the separation of no-carrier-added 211At/211gPo from 209Bi target irradiated by alpha-beam in cyclotron.

Author

Zona, C., Bonardi, M. L., Groppi, F., Morzenti, S., Canella, L., Persico, E., Menapace, E., Alfassi, Z. B., Abbas, K., Holzwarth, U., and Gibson, N.

Subjects
ALPHA decay, ISOTOPE separation, BISMUTH, CYCLOTRONS, RADIOCHEMICAL research
Abstract

We present a fast and effective wet-chemistry method, used to obtain the pure alpha-emitter 211At/211gPo ( T 1/2 = 7.214 h/516 ms), produced by 209Bi(α,2n) reaction in NCA form. It is a selective radiochemical separation of the At radionuclides from the target and the impurities, characterized by a radionuclidic purity close to 100%, based on the dissolution and the dilution of the irradiated target in acidic medium, on the extraction with DIPE, followed by the back-extraction with NaOH. As a result, we obtain a yield greater than 90–97% in a range from 0.75M to 2.00M. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

47. Cyclotron production of 211At/211gPo by 209Bi(α,2n) reaction.

Author

Morzenti, S., Bonardi, M. L., Groppi, F., Zona, C., Persico, E., Menapace, E., and Alfassi, Z. B.

Subjects
CYCLOTRONS, ASTATINE, BISMUTH, LINEAR energy transfer, POLONIUM, RADIOTHERAPY
Abstract

Astatine-211 ( T 1/2 = 7.214 h) is an α-emitter at secular equilibrium by EC with its ultra-short-lived α-emitting daughter, polonium-211g ( T 1/2 = 0.516 s), with a high Linear Energy Transfer (LET — 130 eV·nm−1) and a half-life suitable for metabolic radiotherapy; the overall α branching of the 211At/211gPo system is 100%. The direct production of 209Bi(α,2n)211At/211gPo seems the most satisfactory method; Bi targets were irradiated at JRC-Ispra Cyclotron of European Commission, EC, using α-energy higher than 28.61 MeV in order to produce, via 209Bi(α,3n) reaction, small amounts of the γ-emitter 210At (used as internal spike). [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results